Cover Image
市場調查報告書

Anastrozole的中國市場:2010年∼2019年

Investigation Report on China Anastrozole Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 337519
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Anastrozole的中國市場:2010年∼2019年 Investigation Report on China Anastrozole Market, 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 30 Pages
簡介

中國的Anastrozole需求,從2010年到2014年之間,以4.89%的年複合成長率擴大,2014年達1億8,400萬人民幣。這個市場上,美國的AstraZeneca佔銷售額92%,具壓倒性的佔有率。

本報告提供中國的Anastrozole的專利及核準情況、銷售額、銷售量的變化與預測、價格趨勢、主要的製藥公司與其市場佔有率、競爭環境與其展望、主要製造商的簡介等。

第1章 Anastrozole的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Anastrozole的市場簡介

  • 專利、核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國的Anastrozole銷售情形

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的主要Anastrozole製造商市場佔有率

  • 銷售額為基礎的市場佔有率
  • 銷售量為基礎的市場佔有率

第5章 中國的Anastrozole的劑型的相關調查

  • 各劑型的市場佔有率:銷售額為基礎的
  • 各劑型的市場佔有率:銷售量為基礎的

第6章 中國的醫院的Anastrozole的標準價格

  • Yangtze River Pharmaceutical Group
  • AstraZeneca
  • Huapont Pharm
  • Wanma Group
  • Zhejiang Hisun Pharmaceutical Co.,Ltd.

第7章 中國市場中Anastrozole的主要製藥公司

  • AstraZeneca
  • Yangtze River Pharmaceutical Group
  • Huapont Pharm
  • Wanma Group
  • Zhejiang Hisun Pharmaceutical Co.,Ltd.

第8章 中國的Anastrozole的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1508302

As a non-steroidal aromatase-inhibiting, anastrozole works by inhibiting the synthesis of estrogen in post-menopausal women which can increase the severity of breast cancer. Besides, anastrozole has little influence on adrenocortical steroid or aldosterone.

Originally developed by AstraZeneca, anastrozole was approved by FDA as the second-line medicine for breast cancer in 1995 and later in 2000 became the first-line drug. In 2002, it was approved as the therapy for postmenopausal women with localized breast cancer which is ER positive.

The incidence of breast cancer has kept growing since the 1970s in the world. With decreasing fertility rate, environmental changes, increasing pressure and growing number of women aged 50-54 who face greater risk of breast cancer, the incidence of breast cancer in China grows at a rate which is 1-2% higher than that in other countries and doubles that of the world average. As the malignant tumor with the highest incidence, breast cancer will report 2.5 million cases by 2021 in China. Hence a huge market for anastrozole.

The demand for anastrozole is gradually growing. According to CRI's market survey, anastrozole sales has went up slightly to CNY 184 million in 2014 with CAGR during the period of 2010-2014 reaching 4.89%. And AstraZeneca (US), Yangtze River Pharmaceutical Group, Huapont Pharm, Wanma Group and Hisun occupy the market, among which AstraZeneca (US) had the largest market share of about 92% for sales value in 2014.

Readers can get at least the following information through this report:

  • market size of anastrozole in China
  • competitive landscape of anastrozole market in China
  • price of anastrozole made by different enterprises in China
  • market outlook of anastrozole in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor drugs
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Anastrozole

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Anastrozole in China

  • 2.1. Patent and Approval Information of Anastrozole in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Anastrozole Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Anastrozole Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Anastrozole in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Anastrozole in Chinese Hospitals in 2014

  • 6.1. Yangtze River Pharmaceutical Group
  • 6.2. AstraZeneca
  • 6.3. Huapont Pharm
  • 6.4. Wanma Group
  • 6.5. Zhejiang Hisun Pharmaceutical Co.,Ltd.

7. Major Manufacturers of Anastrozole in Chinese Market, 2010-2014

  • 7.1. AstraZeneca
  • 7.2. Yangtze River Pharmaceutical Group
  • 7.3. Huapont Pharm
  • 7.4. Wanma Group
  • 7.5. Zhejiang Hisun Pharmaceutical Co.,Ltd.

8. Market Outlook of Anastrozole in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Anastrozole in China
  • Chart Anastrozole Sales in China
  • Chart Sales Value of Anastrozole in China, 2010-2014
  • Chart Sales Value of Anastrozole in Some Regions in China, 2010-2014
  • Chart Sales Volume of Anastrozole in China, 2010-2014
  • Chart Sales Volume of Anastrozole in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Anastrozole Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Anastrozole Made by AstraZeneca (US) in China, 2010-2014
  • Chart Sales Value and Market Share of Anastrozole Made by Yangtze River Pharmaceutical Group in China, 2010-2014
  • Chart Sales Value and Market Share of Anastrozole Made by Huapont in China, 2010-2014
  • Chart Sales Value and Market Share of Anastrozole Made by Other Manufacturers in China, 2010-2014
  • Chart Price of Anastrozole Made by Yangtze River Pharmaceutical Group in Some Chinese Cities in 2014
  • Chart Price of Anastrozole Made by AstraZeneca (US) in Some Chinese Cities in 2014
  • Chart Price of Anastrozole Made by Huapont in Some Chinese Cities in 2014
  • Chart Price of Anastrozole Made by Wanma Group in Some Chinese Cities in 2014
  • Chart Price of Anastrozole Made by Hisun in Some Chinese Cities in 2014
Back to Top